How has been the historical performance of Emcure Pharma?

Answer:Emcure Pharma has shown a consistent growth trajectory in its financial performance over the past three years, with significant increases in net sales and profits.

Breakdown:
In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, up from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. Total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure, excluding depreciation, also rose to 6,421.62 Cr in March 2025, compared to 5,428.53 Cr in March 2024 and 4,804.63 Cr in March 2023. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, up from 1,286.71 Cr in March 2024 and 1,227.09 Cr in March 2023. Profit before tax reached 971.35 Cr in March 2025, a rise from 727.23 Cr in March 2024 and 747.22 Cr in March 2023. The profit after tax also saw an increase to 707.47 Cr in March 2025, compared to 527.58 Cr in March 2024 and 561.85 Cr in March 2023. The consolidated net profit for March 2025 was 681.33 Cr, up from 498.18 Cr in March 2024 and 532.02 Cr in March 2023. Earnings per share (EPS) improved to 35.96 in March 2025 from 27.5 in March 2024 and 29.42 in March 2023. Overall, Emcure Pharma has demonstrated solid growth in both revenue and profitability metrics over the observed period.